-
Tytuł:
-
Doravirine-associated resistance mutations in antiretroviral therapy naïve and experienced adults with HIV-1 subtype C infection in Botswana.
-
Autorzy:
-
Bareng OT; Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana; Department of Medical Sciences, Faculty of Allied Health Professions, University of Botswana, Gaborone, Botswana.
Seselamarumo S; Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana; Department of Biological Sciences, Faculty of Science, University of Botswana, Gaborone, Botswana.
Seatla KK; Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana; Department of Medical Sciences, Faculty of Allied Health Professions, University of Botswana, Gaborone, Botswana.
Choga WT; Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana; Division of Human Genetics, Department of Pathology, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.
Bakae B; Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
Maruapula D; Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana; Department of Biological Sciences, Faculty of Science, University of Botswana, Gaborone, Botswana.
Kelentse N; Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana; Department of Medical Sciences, Faculty of Allied Health Professions, University of Botswana, Gaborone, Botswana.
Moraka NO; Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana; Division of Medical Virology, Stellenbosch University, Cape Town, South Africa.
Mokaleng B; Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana; Department of Medical Sciences, Faculty of Allied Health Professions, University of Botswana, Gaborone, Botswana.
Mokgethi PT; Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana; Department of Biological Sciences, Faculty of Science, University of Botswana, Gaborone, Botswana.
Ditlhako TR; Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
Pretorius-Holme M; Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
Mbulawa MB; Ministry of Health, Republic of Botswana, Gaborone, Botswana.
Lebelonyane R; Ministry of Health, Republic of Botswana, Gaborone, Botswana.
Bile EC; FHI 360, Department of Clinical Sciences, Durham, North Carolina, USA.
Gaolathe T; Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
Shapiro R; Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana; Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
Makhema JM; Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana; Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
Lockman S; Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana; Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA; Brigham and Women's Hospital, Boston, Massachusetts, USA.
Essex M; Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana; Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
Novitsky V; Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana; Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
Mpoloka SW; Department of Biological Sciences, Faculty of Science, University of Botswana, Gaborone, Botswana.
Moyo S; Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana; Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
Gaseitsiwe S; Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana; Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA. Electronic address: .
-
Źródło:
-
Journal of global antimicrobial resistance [J Glob Antimicrob Resist] 2022 Dec; Vol. 31, pp. 128-134. Date of Electronic Publication: 2022 Aug 13.
-
Typ publikacji:
-
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
-
Język:
-
English
-
Imprint Name(s):
-
Original Publication: Amsterdam : Published by Elsevier Ltd. on behalf of International Society of Chemotherapy for Infection and Cancer
-
MeSH Terms:
-
HIV-1*/genetics
Anti-HIV Agents*/pharmacology
Anti-HIV Agents*/therapeutic use
HIV Infections*/epidemiology
Adult ; Humans ; Drug Resistance, Viral/genetics ; Cross-Sectional Studies ; Retrospective Studies ; Botswana ; Mutation
-
References:
-
Pediatr Infect Dis J. 2019 Aug;38(8):835-839. (PMID: 31033912)
J Antimicrob Chemother. 2022 Mar 31;77(4):1119-1124. (PMID: 35134966)
J Infect Dis. 2013 Jun 15;207 Suppl 2:S45-8. (PMID: 23687288)
J Antimicrob Chemother. 2019 Mar 1;74(3):614-617. (PMID: 30476106)
J Acquir Immune Defic Syndr. 2015 Apr 1;68(4):463-71. (PMID: 25564107)
Nucleic Acids Res. 2014 Oct;42(18):e144. (PMID: 25120265)
AIDS. 2019 May 1;33(6):1073-1082. (PMID: 30946161)
Clin Infect Dis. 2019 Feb 1;68(4):535-544. (PMID: 30184165)
AIDS Behav. 2015 Apr;19(4):601-11. (PMID: 25342151)
J Clin Microbiol. 2015 Aug;53(8):2581-92. (PMID: 26041893)
Antimicrob Agents Chemother. 2021 Nov 17;65(12):e0121621. (PMID: 34570651)
Antimicrob Agents Chemother. 2016 Mar 25;60(4):2241-7. (PMID: 26833152)
Bioinformatics. 2000 Apr;16(4):400-1. (PMID: 10869039)
Lancet HIV. 2018 May;5(5):e211-e220. (PMID: 29592840)
J Int AIDS Soc. 2019 Jan;22(1):e25227. (PMID: 30663278)
N Engl J Med. 2019 Jul 18;381(3):230-242. (PMID: 31314967)
Int J Antimicrob Agents. 2019 Apr;53(4):515-519. (PMID: 30769200)
Curr Opin HIV AIDS. 2018 Jul;13(4):291-293. (PMID: 29702493)
Antivir Ther. 2021 May;26(3-5):69-78. (PMID: 35485331)
J Int AIDS Soc. 2021 May;24(5):e25706. (PMID: 33943000)
J Acquir Immune Defic Syndr. 2019 Aug 1;81(4):463-472. (PMID: 30985556)
J Antimicrob Chemother. 2021 Jan 1;76(1):130-134. (PMID: 32974670)
J Antimicrob Chemother. 2022 Feb 2;77(2):474-482. (PMID: 34741609)
J Antimicrob Chemother. 2020 Apr 1;75(4):1026-1030. (PMID: 31976534)
AIDS. 2018 Aug 24;32(13):1899-1902. (PMID: 29894383)
AIDS. 2018 Jul 17;32(11):1543-1546. (PMID: 29762166)
J Antimicrob Chemother. 2016 May;71(5):1361-6. (PMID: 26929269)
AIDS Res Ther. 2019 Feb 22;16(1):5. (PMID: 30795780)
Viruses. 2021 Mar 31;13(4):. (PMID: 33807382)
Infect Genet Evol. 2013 Oct;19:337-48. (PMID: 23660484)
-
Grant Information:
-
U41 HG006941 United States HG NHGRI NIH HHS; U2G GH001911 United States GH CGH CDC HHS; D43 TW009610 United States TW FIC NIH HHS; U01 GH000447 United States GH CGH CDC HHS; United States PEPFAR PEPFAR; K24 AI131928 United States AI NIAID NIH HHS
-
Contributed Indexing:
-
Keywords: Antiretroviral (ART) experienced; Antiretroviral (ART) naive; Botswana; Doravirine; Drug resistance mutations; HIV-1C
-
Substance Nomenclature:
-
0 (Anti-HIV Agents)
913P6LK81M (doravirine)
-
Entry Date(s):
-
Date Created: 20220816 Date Completed: 20221220 Latest Revision: 20230829
-
Update Code:
-
20240104
-
PubMed Central ID:
-
PMC9750894
-
DOI:
-
10.1016/j.jgar.2022.08.008
-
PMID:
-
35973671
-
Objectives: There are limited data on the prevalence of doravirine (DOR)-associated drug resistance mutations in people with HIV (PWH) in Botswana. This cross-sectional, retrospective study aimed to explore the prevalence of DOR-associated resistance mutations among ART-naïve and -experienced PWH in Botswana enrolled in the population-based Botswana Combination Prevention Project (BCPP).
Methods: A total of 6078 HIV-1C pol sequences were analysed for DOR-associated resistance mutations using the Stanford HIV drug resistance database, and their levels were predicted according to the Stanford DRM penalty scores and resistance interpretation. Virologic failure was defined as HIV-1 RNA load (VL) >400 copies/mL.
Results: Among 6078 PWH, 5999 (99%) had known ART status, and 4529/5999 (79%) were on ART at time of sampling. The suppression rate among ART-experienced was 4517/4729 (96%). The overall prevalence of any DOR-associated resistance mutations was 181/1473 (12.3% [95% confidence interval {CI}: 10.7-14.1]); by ART status: 42/212 (19.8% [95% CI: 14.7-25.4]) among ART-failing individuals (VL ≥400 copies/mL) and 139/1261 (11.0% [95% CI: 9.3-12.9]) among ART-naïve individuals (P < 0.01). Intermediate DOR-associated resistance mutations were observed in 106/1261 (7.8% [95% CI: 6.9-10.1]) in ART-naïve individuals and 29/212 (13.7% [95% CI: 9.4-8.5]) among ART-experienced participants (P < 0.01). High-level DOR-associated resistance mutations were observed in 33/1261 (2.6% [95% CI: 1.8-3.7]) among ART-naïve and 13/212 (6.1% [95% CI: 3.6-10.8]) among ART-failing PWH (P < 0.01). PWH failing ART with at least one EFV/NVP-associated resistance mutation had high prevalence 13/67 (19.4%) of high-level DOR-associated resistance mutations.
Conclusion: DOR-associated mutations were rare (11.0%) among ART-naive PWH but present in 62.7% of Botswana individuals who failed NNRTI-based ART with at least one EFV/NVP-associated resistance mutation. Testing for HIV drug resistance should underpin the use of DOR in PWH who have taken first-generation NNRTIs.
Competing Interests: Declaration of Competing Interest None declared.
(Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved.)
